高级检索
当前位置: 首页 > 详情页

Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.

文献详情

资源类型:
Pubmed体系:
机构: [1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Endocrinology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [3]Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China [4]Central Lab of Binzhou People’s Hospital, Central Lab of Binzhou People’s Hospital, Shandong, China [5]Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [6]Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, China [7]School of Pharmaceutical, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [8]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [9]Guangdong Provincial Institute of Sports Science, Guangzhou, Guangdong, China [10]Division of Hypothalamic Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA [11]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
出处:
ISSN:

摘要:
Impaired hepatic fatty acids oxidation results in lipid accumulation and redox imbalance, promoting the development of fatty liver diseases and insulin resistance. However, the underlying pathogenic mechanism is poorly understood. Krüppel-like factor 16 (KLF16) is a transcription factor that abounds in liver. We explored whether and by what mechanisms KLF16 affects hepatic lipid catabolism to improve hepatosteatosis and insulin resistance. KLF16 expression was determined in patients with non-alcoholic fatty liver disease (NAFLD) and mice models. The role of KLF16 in the regulation of lipid metabolism was investigated using hepatocyte-specific KLF16-deficient mice fed a high-fat diet (HFD) or using an adenovirus/adeno-associated virus to alter KLF16 expression in mouse primary hepatocytes (MPHs) and in vivo livers. RNA-seq, luciferase reporter gene assay and ChIP analysis served to explore the molecular mechanisms involved. KLF16 expression was decreased in patients with NAFLD, mice models and oleic acid and palmitic acid (OA and PA) cochallenged hepatocytes. Hepatic KLF16 knockout impaired fatty acid oxidation, aggravated mitochondrial stress, ROS burden, advancing hepatic steatosis and insulin resistance. Conversely, KLF16 overexpression reduced lipid deposition and improved insulin resistance via directly binding the promoter of peroxisome proliferator-activated receptor α (PPARα) to accelerate fatty acids oxidation and attenuate mitochondrial stress, oxidative stress in db/db and HFD mice. PPARα deficiency diminished the KLF16-evoked protective effects against lipid deposition in MPHs. Hepatic-specific PPARα overexpression effectively rescued KLF16 deficiency-induced hepatic steatosis, altered redox balance and insulin resistance. These findings prove that a direct KLF16-PPARα pathway closely links hepatic lipid homeostasis and redox balance, whose dysfunction promotes insulin resistance and hepatic steatosis. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学
第一作者:
第一作者机构: [1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构: [1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China [3]Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China [10]Division of Hypothalamic Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA [11]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [*1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, China [*2]Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China [*3]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号